linjc16/ctgov huggingface dataset:
The Effect of Anodal tDCS on Motor Learning in Multiple Sclerosis

Study Overview
=================
Brief Summary
-----------------
The current study investigates the effects of tDCS in patients with multiple sclerosis (MS). The investigators hypothesize that anodal tDCS will increase motor performance in patients with MS.

Conditions
-----------------
Anodal tDCS, Recruitment Curves

Intervention / Treatment
-----------------
* Device: Transcranial Direct Current Stimulation (tDCS) (Neuroconn DC-stimulator)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: at least 18 years old male and female Exclusion Criteria: relapse in the last 3 months when not suitable for tDCS (screening) if TMS measures can not be completed

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Anodal tDCS<br> | Device: Transcranial Direct Current Stimulation (tDCS) (Neuroconn DC-stimulator)<br>* The anode will be fixed over the primary motor cortex. The cathode will be fixed over the contralateral supraorbital region.<br>* Other names: Neuroconn DC-stimulator;|
| Sham Comparator: Sham tDCS<br> | Device: Transcranial Direct Current Stimulation (tDCS) (Neuroconn DC-stimulator)<br>* The anode will be fixed over the primary motor cortex. The cathode will be fixed over the contralateral supraorbital region.<br>* Other names: Neuroconn DC-stimulator;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Motor performance on a unimanual sequence learning task | Patients were instructed to perform a unimanual sequence-learning task consisting of sequential finger presses. The following parameters were measured: Correct sequences/mean inter tap interval (ITI), percentage correct key presses/mean ITI, percentage correct sequences, percentage correct key presses, mean ITI, and mean correct sequences in the performance interval. | Baseline, during training and POST (30 min after baseline) intervention |
Gut Microbiota Metagenomics for Chronic Liver Disease

Study Overview
=================
Brief Summary
-----------------
Gut microbiota modulation has effect on chronic liver disease

Detailed Description
-----------------
Chronic liver disease has been known as a disease of the liver which lasts over a period of 6-month. It consists of inflammation, hepatitis, cirrhosis, hepatocellular carcinoma. Gut microbiota plays an important roles in the chronic liver disease. It can suppress the progression of the liver disease by moulation gut microbiota. The investigators are still evaluating the effect of gut microbiota on the liver disease.

Official Title
-----------------
Research Based on Gut Microbiota Metagenomics for Prevention of Chronic Liver Disease

Conditions
-----------------
Liver Disease Chronic

Intervention / Treatment
-----------------
* Other: DNA extraction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 19+ Normal : AST or ALT level < 50IU/L, BMI < 25 Liver disease : AST or ATL level ≥ 50IU/L, BMI ≥ 25 Patients hospitalized with chronic liver disease (viral hepatitis, alcoholic liver disease, non-alcoholic liver disease, cirrhosis, liver cancer) Exclusion Criteria: Normal : AST or ATL level ≥ 50IU/L, BMI ≥ 25 Liver disease : AST or ALT level < 50IU/L, BMI < 25 If the patient refuses

Ages Eligible for Study
-----------------
Minimum Age: 31 Years
Maximum Age: 82 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Fecal DNA<br>Extraction fecal DNA and compare disease group to normal group | Other: DNA extraction<br>* Extraction fecal DNA and compare disease group to normal group<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fecal DNA | Compare the species and proportions of the gut microbiome | 10 years | 
| Liver enzyme | Compare the liver enzyme level | 10 years | 
| BMI | Compare the body mass index | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Liver, Fecal, Gut microbiota
Price Changes and Hypothetical Food Purchases in Adult Grocery Shoppers

Study Overview
=================
Brief Summary
-----------------
The goal of the proposed study is to apply experimental economics in an online grocery store shopping model to examine the effects of pricing on hypothetical food purchases

Detailed Description
-----------------
Participants will be lean and overweight primary grocery shoppers aged 18 years and older. Participants will be considered lean if their body mass index (BMI = kg/m2) is less than 29.9, overweight if their BMI is greater than or equal to 30.12 To meet eligibility for the study, participants must be the guardian of a child at least 2 years or older, do the primary grocery shopping for the family, they must also report being weekly household grocery shoppers, and purchase the majority of their household's groceries once a week.

Official Title
-----------------
Experimental Analysis of Price Changes and Food Purchases in Obese and Lean Mothers

Conditions
-----------------
Effect of Taxes and Subsides on Food Purchases in Mothers

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 or older primary shopper in the household, at least one child over 2 years of age Exclusion Criteria: eating disorders, not liking study foods

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Energy Purchased as a Result of Taxes. | Change in total calories as a result of taxes of 12.5% and 25%. | Study Completion | 
| Change in Energy Purchased as a Result of Subsidies | Change in total calories as a result of subsidies of 12.5% and 25%. | Study Completion |
The Imaging Genetic Study of Schizophrenia and Family

Study Overview
=================
Brief Summary
-----------------
To investigate the brain abnormalities and the association with gene in schizophrenia patients and their relatives.

Conditions
-----------------
Schizophrenia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of schizophrenia（DSM-IV） total score of PANSS>64 Exclusion Criteria: other psychiatric disease, organic disease neurological disease unstable physiological status age>65 pregnant

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| schizophrenia patients,untreated<br> | |
| schizophrenia relatives<br> | |
| controls<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the association between gene and fMRI in schizophrenia patients |  | 30 days after diagnosis |
A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.

Study Overview
=================
Brief Summary
-----------------
A study to determine the ability of different doses of PF-610,355 to open the airways in asthmatic patients by comparison with placebo and a marketed drug that also opens the airways in asthmatic patients.

Official Title
-----------------
A Phase IIA Randomised, Double-blind, Double Dummy, Placebo and Active Controlled 5-Way Cross-over Trial to Examine the Bronchodilator Effects of PF-610,355 and to Test for Superiority Versus Placebo in Reversible Asthmatic Patients

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: PF-610,355
* Drug: Salmeterol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Reversible asthmatic patients (>15% increase in FEV1 following 200ug salbutamol). FEV1 greater than or equal to 60% predicted Stable disease for at least the previous 3 months Exclusion Criteria: Subjects requiring rescue medication on greater than 2 occasions in the 72 hours prior to screening Subjects with a history of pulmonary disease other than asthma.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: PF-610,355|nan|
|Drug: Salmeterol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peak and Trough (24 hour post dose) FEV1. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peak and trough (24 hour post dose) PEFR |  |  | 
| FEV1 and PEFR measurements to 32 hours post dose. |  |  | 
| Pharmacokinetics of PF-610,355 and salmeterol |  |  | 
| Safety/Pharmacodynamic end points - pulse rate, blood pressure, QTcF, plasma potassium, blood glucose and AEs. |  |  |
Changes in Out-patient Visits in Taiwan During the Time of Global COVID-19 Pandemic

Study Overview
=================
Brief Summary
-----------------
The COVID-19 pandemic becomes a global challenge. This study aims to analyze the possible changes in out-patient visits during the time of COVID-19 pandemic between January and June, 2020, compared with the same period in 2019, and the impact of the related healthy policies.

Detailed Description
-----------------
Using the statistical data of the Health Insurance Bureau, this study aims to analyze the possible changes in out-patient visits during the time of COVID-19 pandemic between January and June, 2020, compared with the same period in 2019, and the impact of the related healthy policies.

Official Title
-----------------
An Analysis of Changes in Out-patient Visits in Taiwan During the Time of Global COVID-19 Pandemic

Conditions
-----------------
Patient Preference

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients visited the out-patient clinic using the health insurance cards. Exclusion Criteria: patients visited the out-patient clinic without using the health insurance cards.
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the number of the out-patient visits | Collect the number of the out-patient visits, comparing with that during the same period last year | 6 months |
Heart Failure Management in Azerbaijan

Study Overview
=================
Brief Summary
-----------------
This study is proposed to determined a national database of the etiologies, clinical and the demographic profile, using diagnostic tests and treatment of outpatients with chronic heart failure in Azerbaijan population.

Detailed Description
-----------------
Chronic heart failure remains the leading cause of hospitalization for those over the age of 65 and expected to increase over the next 25 years with advancing life span. Being a progressive syndrome, CHF decreases the quality of life and place an economic burden on health care system. Advanced technologies in interventional cardiology, better organization of angiographic laboratories and primary prevention of coronary artery disease as the leading cause of HF, allowed warning its development in CAD patients. But the incidence and prevalence of CHF continue to increase with age as heart failure with preserved ejection fraction predominates in elderly patients. For the moment more than 23 million people over the world suffer from heart failure. The prevalence of these patients remains very high even in USA - over 5.8 million.However, there is no any database for heart failure patient in Azerbaijan.The purpose of this study is to compose a national database of the etiologies, clinical and demographic characteristics, using diagnostic tests and management of outpatients heart failure in Azerbaijan population.

Official Title
-----------------
The Clinical Profiles and Treatment Management of Chronic Heart Failure in Azerbaijan

Conditions
-----------------
Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion : Patients >18 years olds Clinical diagnosis of heart failure NYHA class II-IV heart failure Exclusion : Patients <18 years old Failure to obtain informed consent Pregnant or lactating Previous cardiac transplantation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Heart failure related hospitalization | Heart failure related hospitalization within 6 months | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heart failure
Regional Differences in Human Immunodeficiency Virus (HIV) Testing

Study Overview
=================
Brief Summary
-----------------
This retrospective observational study aims at the examination of regional differences in the procedure of referral for serological HIV testing between eastern (new) and western (old) German federal states.

Detailed Description
-----------------
Increasing incidence of HIV infections urges early recognition and timely introduction of therapy. Regional differences in referral approach and patient behavior are presumably associated with considerable delays in infection recognition and therapy onset. Comparison of records of new cases which were diagnosed in 2014 in several eastern federal states and a major western German city is expected to disclose whether the regionally preferred type of the primary care institution affects the time point of first diagnosis and the elapsed time since the emergence of the infection, as assessed by Cluster of Differentiation 4 positive (CD4+) lymphocyte counts and manifestation of clinical symptoms of immune deficiency.

Official Title
-----------------
Regional Differences in Human Immunodeficiency Virus (HIV) Testing Procedures in Eastern German Federal States

Conditions
-----------------
HIV Seropositivity, CD4+ T Lymphocytopenia

Intervention / Treatment
-----------------
* Other: Medical record review


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: first-time HIV seropositivity Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Medical record review|Review of medical records of patients diagnosed for the first time as HIV seropositivity|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Type of HIV-verifying medical institution | Medical Institution (university hospital, general practitioner, specialized medical office) which has diagnosed HIV seropositivity for the first time | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CD4+ lymphocyte counts | Number of CD4+ lymphocytes at the time of HIV diagnosis | 1 day | 
| Symptoms of AIDS-related diseases | Presence of AIDS-related disease symptoms at the time of first HIV seropositivity diagnosis | 1 day |
NaROA STUDY: National Register of Open Abdomen

Study Overview
=================
Brief Summary
-----------------
National Register of Open Abdomen Open Abdomen Procedure (Observational and Prospective Study)

Detailed Description
-----------------
The open abdomen technique has widely been proven useful in the treatment of traumatic patients, but its indication in non-traumatic patients with catastrophic abdomen (peritonitis, ischaemia, pancreatitis) generates controversy. Its heterogeneous implementation is based on insufficient evidence and originated in health systems very different from ours. Its low prevalence imposes the need for a multicentre study. AIMS : Establish a national, prospective, multi-centre national registry of non traumatic patients with open abdominal indication whether or not they undergo damage control surgery and open abdomen for: Describe in real time the indications, surgical technique, materials, time, risk factors, definitive closure, reinterventions and complications according to the Clavien-Dindo classification and mortality. Compare the results of the application or non-application of the open abdomen in non-traumatic patients between the different participating centers. Set the limits of the open abdomen in non-traumatic patients indication.

Official Title
-----------------
NaROA STUDY: OBSERVATIONAL, PROSPECTIVE, MULTICENTRIC, NATIONAL OPEN ABDOMEN REGISTRY FOR THE ANALYSIS OF INDICATIONS AND PRONOTIC FACTORS OF MORBI-MORTALITY IN PATIENTS UNDERGOING EMERGENCY SURGERY BY GENERAL SURGERY.

Conditions
-----------------
Open Abdomen Technique

Intervention / Treatment
-----------------
* Procedure: Open abdomen procedure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Indication to Open Abdomen in non-trauma patients Informed consent Exclusion Criteria: Open Abdomen in trauma patients No indication to Open Abdomen Informed consent refusal
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Open abdomen procedure<br>All patients underwent to open abdomen procedure | Procedure: Open abdomen procedure<br>* All patients underwent to open abdomen procedure<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OPEN ABDOMEN: NON-TRAUMATIC ABDOMINAL EMERGENCIES | The open abdomen technique has widely been proven useful in the treatment of traumatic patients, but its indication in non-traumatic patients with catastrophic abdomen (peritonitis, ischaemia, pancreatitis) generates controversy. Its heterogeneous implementation is based on insufficient evidence and originated in health systems very different from ours. Its low prevalence imposes the need for a multicentre study. | two years |
Objective Measurements of Lens Opacification After Intravitreal Injections

Study Overview
=================
Brief Summary
-----------------
The main hypothesis is the opacification of the lens would be increase by the IVT. The opacification of the lens can be objectived by : the objective scatter index (OSI) on the OQAS device the average lens density (ALD) on the IOLMaster device. Eligible patients will be followed at least 12 months after in intravitreal injection and the opacification of their lens is regularly controlled with OSI and ALD. The objective is to study the dynamics of lens opacification in IVT-treated eyes evaluated by OSI for at least 1 year.

Official Title
-----------------
Objective Measurements of Lens Opacification After Intravitreal Injections (MOC-IVT)

Conditions
-----------------
Lens Opacification, Intravitreal Injections (IVT)

Intervention / Treatment
-----------------
* Diagnostic Test: Measurement of lens opacification


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: An indication of an intravenous injection of a dexamethasone 700 μg (Ozurdex®) or anti-VEGF for at least one of the two eyes for macular edema or neovessels linked to DMLA, retinal venous occlusion, diabetic macular edema or posterior uveitis Phake patient, at least of the injected eye Exclusion criteria: - Pseudophakia of the injected eye

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Measurement of lens opacification|Measurement of OSI and ALD at inclusion and during post-IVT follow-up visits to M3, M6, and M12, +/- M18, +/- M24 and +/- M30.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Value of the OSI (Objective Scatter Index) in one year of follow-up after IVT |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cataract, objective scatter index (OSI), average lens density (ALD)